Previous 10 | Next 10 |
Results from three clinical trials expected in 2020 including the Phase 3 trial of OTIVIDEX™ in Ménière’s disease Current capital funds operations into 2021 Conference call and webcast today at 4:30 p.m. ET SAN DIEGO, Feb. 27, 2020 (GLOBE ...
SAN DIEGO, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that David A. Weber, Ph.D., president and chief executive officer, is scheduled to present at ...
SAN DIEGO, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the fourth quarter and full year 2019 as well as provide ...
SAN DIEGO, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced preclinical results from the company’s gene therapy collaboration with Applied Genetic ...
Otonomy ( OTIC +1% ) provides an update on its product pipeline. More news on: Otonomy, Inc., Healthcare stocks news, Read more ...
Three programs with clinical trial results in 2020 including OTIVIDEX™ Phase 3 trial in Ménière’s disease Current capital funds operations into 2021 SAN DIEGO, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceuti...
Gainers: CLPS (NASDAQ: CLPS ) +68% . More news on: CLPS Incorporation, Microbot Medical Inc., Proteostasis Therapeutics, Inc., Stocks on the move, Read more ...
Soleno Therapeutics (NASDAQ: SLNO ) +15% . More news on: Soleno Therapeutics, Inc., Proteostasis Therapeutics, Inc., Microbot Medical Inc., Stocks on the move, Read more ...
Gainers: NLNK +14.3% . OTIC +5.2% . PD +4.1% . KNSL +3.0% . CLSD +2.9% . More news on: NewLink Genetics Corporation, Otonomy, Inc., PagerDuty, Inc., Stocks on the move, , News on ETFs Read more ...
Oppenheimer starts Otonomy (NASDAQ: OTIC ) with an Outperform rating and $8 price target, a 217% upside. The company has a Very Bullish average Sell Side rating . More news on: Otonomy, Inc., Healthcare stocks news, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC) today announced that it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) indicating that the company’s shares would be suspended from trading on Nasdaq effective at...
SAN DIEGO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC) today announced that the company’s board of directors, after considering strategic options, has approved and adopted a Plan of Liquidation and Dissolution (“Plan of Dissolution”) that would include...